It is the deadliest parasitic disease killing over one million people each year. 90 % of the deaths occur south of the Sahara desert and most are under five-year-old children. Generic plaquenil uses Effect of plaquenil on free light chains Comparing the viability of chloroquine treated ring and trophozoite stage P. falciparum by monitoring their glycolytic activity. The ability of ring stage parasites to survive drug exposure and. Etiology/BacteriologyPathogenesisLife CycleSickle Cell ResistanceClinical FeaturesDiagnosisTreatmentPreventionHost Immune ResponseReferences P. falciparum strain 3D7 Pf3D7 was derived from isolate NF54 by limiting dilution. The complete genome of Pf3D7 has been sequenced GenBank LN999946.1. Pf3D7 can be obtained from the European Malaria Reagent Repository or the Malaria Research and Reference Reagent Resource Center MR4 and is sensitive to a panel of antimalarial compounds including chloroquine and pyrimethamine. Even within tropical and subtropical areas, malaria does not usually occur at high altitudes (over 1500 meters), during colder seasons, in countries of successful malaria programs or in deserts. In addition to Africa, malaria occurs in South and Southeast Asia, Central and South America, the Caribbean and the Middle East. Chloroquine schizont p falciparum CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM MALARIA IN., Plasmodium falciparum - microbewiki Stopping plaquenil5 line raster oct plaquenil Higher mean parasitaemia in untreated oligosymptomatic carriers of overtly chloroquine-resistant P. falciparum than in carriers of more sensitive parasites was another indication of higher viability and biological advantage of chloroquine-resistant P. falciparum that may conceivably have clinical implications. Chloroquine resistance of Plasmodium falciparum a.. Plasmodium falciparum N-Myristoyltransferase.. Reemergence of Chloroquine-Sensitive Plasmodium falciparum.. Therapy and prophylaxis of malaria have become highly complex due to widespread resistance by P. falciparum to chloroquine and other antimalarials and to a lesser extent, resistance by P. vivax to chloroquine P. vivax and P. ovale. Chloroquine or hydroxychloroquine remains an effective choice for all P. vivax and P. ovale infections except for P. vivax infections acquired in Papua New Guinea or Indonesia. The regimens listed for the treatment of P. falciparum are also effective and may be used. Chloroquine CQ has been the mainstay of treatment of malaria for decades. This cost-effective and safe drug has become ineffective for treatment of falciparum malaria in many parts of the world due to development of resistance by the parasite. In addition CQ is not gametocytocidal for P. falciparum and thus cannot block transmission. The extent of problem of chloroquine resistance in P.